Investing.com -- Denali Therapeutics Inc (NASDAQ:DNLI) stock rose 5.7% on Thursday after the company announced a $275 million synthetic royalty funding agreement with Royalty Pharma plc (NASDAQ:RPRX) ...

The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...

Denali Therapeutics and Royalty Pharma entered a $275 million royalty funding agreement based on future sales of tividenofusp alfa.

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic ...

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...

Denali Therapeutics ( ($DNLI) ) has issued an update. On December 4, 2025, Denali Therapeutics entered into a $275 million synthetic royalty ...

Denali Therapeutics ( ($DNLI) ) just unveiled an announcement. On December 4, 2025, Denali Therapeutics held its Investor Day, updating ...

One of the best aspects of our job is the wide variety of vehicles we get to test and evaluate.Driving supercars and off-road ...

Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.